Editorial & Advertiser disclosure
Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Pfizer CEO Warns German Investments at Risk Over Drug Price Policies
Impact of German Drug Price Policies on Pharmaceutical Investments
By Maggie Fick, Bhanvi Satija and Patricia Weiss
Pfizer’s Review of Investment Plans
LONDON/FRANKFURT, June 10 (Reuters) – Pfizer is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter to Chancellor Friedrich Merz, citing the government’s policy proposals that would lower drug prices.
The letter, dated June 9 and seen by Reuters on Wednesday, was first reported by German business newspaper Handelsblatt.
Concerns Over Investment Predictability
Bourla wrote that the proposals call into question the predictability required for the pharmaceutical industry’s long-term investment decisions.
Potential Changes in Pfizer’s Engagements
“As a result, we are reviewing our external engagements as well as the timing, scope, and future prioritization of certain planned investments in Germany,” the letter read.
Broader Industry Response
It comes the week after U.S.-based Eli Lilly said it would halve its $2.3 billion investment in Germany and German drugmaker Boehringer Ingelheim scrapped its €900 million plans, both citing the government’s planned healthcare cost-cutting measures.
(Reporting by Maggie Fick and Bhanvi Satija in London, and Patricia Weiss in Frankfurt. Editing by Andrew Heavens and Mark Potter)
Leave a comment